These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 2675644)

  • 1. Rapid detoxification from opioid dependence.
    Kosten TR; Krystal JH; Charney DS; Price LH; Morgan CH; Kleber HD
    Am J Psychiatry; 1989 Oct; 146(10):1349. PubMed ID: 2675644
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase II clinical trials of buprenorphine: detoxification and induction onto naltrexone.
    Kosten TR; Morgan C; Kleber HD
    NIDA Res Monogr; 1992; 121():101-19. PubMed ID: 1406906
    [No Abstract]   [Full Text] [Related]  

  • 3. Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience.
    Amass L; Ling W; Freese TE; Reiber C; Annon JJ; Cohen AJ; McCarty D; Reid MS; Brown LS; Clark C; Ziedonis DM; Krejci J; Stine S; Winhusen T; Brigham G; Babcock D; Muir JA; Buchan BJ; Horton T
    Am J Addict; 2004; 13 Suppl 1(Suppl 1):S42-66. PubMed ID: 15204675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid opioid detoxification with electrosleep and naloxone.
    Westermeyer J
    Am J Psychiatry; 1990 Jul; 147(7):952-3. PubMed ID: 2393441
    [No Abstract]   [Full Text] [Related]  

  • 5. Rapid and ultrarapid opioid detoxification techniques.
    O'Connor PG; Kosten TR
    JAMA; 1998 Jan; 279(3):229-34. PubMed ID: 9438745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Ultra-rapid detoxification of opiate dependent patients: review of the literature, critiques and proposition for an experimental protocol].
    Fontaine E; Godfroid IO; Guillaume R
    Encephale; 2001; 27(2):187-93. PubMed ID: 11407272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone.
    Rosado J; Walsh SL; Bigelow GE; Strain EC
    Drug Alcohol Depend; 2007 Oct; 90(2-3):261-9. PubMed ID: 17517480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Less pain, more gain: buprenorphine-naloxone and patient retention in treatment.
    Renzelli CM; Capretto NA
    J Addict Dis; 2006; 25(3):97-104. PubMed ID: 16956874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treating opiate addiction, Part I. Detoxification and maintenance.
    Harv Ment Health Lett; 2004 Dec; 21(6):4-6. PubMed ID: 15717347
    [No Abstract]   [Full Text] [Related]  

  • 10. Opiate detoxification protocols. A clinical manual.
    Fishbain DA; Rosomoff HL; Cutler R
    Ann Clin Psychiatry; 1993 Mar; 5(1):53-65. PubMed ID: 8394176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pain and continued opioid use in individuals receiving buprenorphine-naloxone for opioid detoxification: secondary analyses from the Clinical Trials Network.
    Potter JS; Chakrabarti A; Domier CP; Hillhouse MP; Weiss RD; Ling W
    J Subst Abuse Treat; 2010 Jun; 38 Suppl 1(Suppl 1):S80-6. PubMed ID: 20307799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Naloxone-induced withdrawal in patients with buprenorphine dependence.
    Nigam AK; Srivastava RP; Saxena S; Chavan BS; Sundaram KR
    Addiction; 1994 Mar; 89(3):317-20. PubMed ID: 8173501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outpatient comparison of buprenorphine and methadone maintenance. I. Effects on opiate use and self-reported adverse effects and withdrawal symptomatology.
    Johnson RE; Fudala PJ; Jaffe JH
    NIDA Res Monogr; 1990; 105():585-6. PubMed ID: 1876130
    [No Abstract]   [Full Text] [Related]  

  • 14. Medical treatment of opioid dependence within the South African context.
    Weich L
    SADJ; 2010 May; 65(4):168-71. PubMed ID: 20632700
    [No Abstract]   [Full Text] [Related]  

  • 15. Technique for greatly shortening the transition from methadone to naltrexone maintenance of patients addicted to opiates.
    Loimer N; Lenz K; Schmid R; Presslich O
    Am J Psychiatry; 1991 Jul; 148(7):933-5. PubMed ID: 2053636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence.
    Mammen K; Bell J
    Expert Opin Pharmacother; 2009 Oct; 10(15):2537-44. PubMed ID: 19708849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergency management of inadvertent accelerated opiate withdrawal in dependent opiate users.
    Lubman D; Koutsogiannis Z; Kronborg I
    Drug Alcohol Rev; 2003 Dec; 22(4):433-6. PubMed ID: 14660133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical treatments for opioid use disorder in Iran: a randomized, double-blind placebo-controlled comparison of buprenorphine/naloxone and naltrexone maintenance treatment.
    Mokri A; Chawarski MC; Taherinakhost H; Schottenfeld RS
    Addiction; 2016 May; 111(5):874-82. PubMed ID: 26639678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clonidine and naltrexone. A safe, effective, and rapid treatment of abrupt withdrawal from methadone therapy.
    Charney DS; Riordan CE; Kleber HD; Murburg M; Braverman P; Sternberg DE; Heninger GR; Redmond DE
    Arch Gen Psychiatry; 1982 Nov; 39(11):1327-32. PubMed ID: 7138234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial.
    Marsch LA; Bickel WK; Badger GJ; Stothart ME; Quesnel KJ; Stanger C; Brooklyn J
    Arch Gen Psychiatry; 2005 Oct; 62(10):1157-64. PubMed ID: 16203961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.